PilgrimAJ, BlakeboroughP.The clinical efficacy of sumatriptan in the acute treatment of migraine. Rev Contemp Pharmacother1994; 5: 295–309
4.
Tfelt-HansenP.Sumatriptan for the treatment of migraine attacks—a review of controlled clinical trials. Cephalalgia1993; 13: 238–44
5.
Tfelt-HansenP.Preliminary analysis of randomized placebo-controlled clinical trials with newer 5HT1D-receptor agonists for the treatment of migraine attacks. In: OlesenJ, Tfelt-HansenP editors. 6th International Headache Research Seminar. Headache Treatment. Trial Methodology and New Drugs.New York: Raven Press, 1997: 253–6
6.
PloskerGL, McTavishD.Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs1994; 47: 622–51
OttervangerJP, StriekerBHCh. Cardiovascular adverse reactions to sumatriptan: cause for concern?CNS Drugs1995; 3: 90–8
12.
DahlöfC.Headache recurrence after subcutaneous sumatriptan. Lancet1992; 339: 525
13.
RapoportAM, VisserWH, CutlerNR, AldertonCJ, PaulsgroveLA, DavisRL, FerrariMD.Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan. Neurology1995; 45: 1505–9
14.
International Headache Society Committee on Clinical Trials in Migraine.Guidelines for controlled trials of drugs in migraine. First edition. Cephalalgia1991; 11: 1–12
15.
PilgrimAJ.Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol1991; 31: 295–9
16.
Tfelt-HansenP.Complete relief (IHS criterion) or no or mild pain (“Glaxo criterion”)? Estimation of relative power in placebo-controlled clinical trials of sumatriptan. In: OlsenJ, Tfelt-HansenP editors. 6th International Headache Research Seminar. Headache Treatment. Trial Methodology and New Drugs.New York: Raven Press, 1997: 157–60
17.
McQuayH, CarrolD, JadadAR, WiffenP, MooreA.Anticonvulsant drugs for management of pain: a systematic review. Br Med J1995; 311: 1047–52
18.
Tfelt-HansenP, SchoenenJ, LauretD.Success rates of combined oral lysine acetylsalicylate and metoclopramide, oral sumatriptan, and placebo depend on initial headache severity. A premininary retrospective analysis. In: OlsenJ, Tfelt-HansenP editors. 6th International Headache Research Seminar. Headache Treatment. Trial Methodology and New Drugs.New York: Raven Press, 1997: 103–6
19.
Multinational Oral Sumatriptan and Cafergot Comparative Study Group.A randomized, double-blind comparison of sumatriptan in the acute treatment of migraine. Eur Neurol1991; 31: 314–22
20.
Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group.A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol1992; 32: 177–84
21.
Geraud G for the International 311C90 Long-term Study Group.Evaluation of the long-term safety and efficacy of zolmitriptan (311C90) in the treatment of migraine. Eur Neurol1996; 36 Suppl 2: 24–7
22.
RederichG, RapoportA, CutlerN, HazelriggR, JamersonB.Oral sumatriptan for the long-term treatment of migraine: clinical findings. Neurology1995; 45 Suppl 7: S15–20
23.
VisserWH, de VriendRHM, JaspersNMWH, FerrariMD.Sumatriptan in clinical practice: a two year review of 453 migraine patients. Neurology1996; 47: 46–51
24.
DahlöfC, EdwardsC, TothAL.Sumatriptan injection is superior to placebo in the acute treatment of migraine—with regard to both efficacy and general well being. Cephalalgia1992; 12: 214–20
